DJIA 17,710.18 -47.73 -0.27%
NASDAQ 4,996.22 -16.90 -0.34%
S&P 500 2,072.20 -5.22 -0.25%
market minute promo

29.80 -0.22 (-0.73%)

Quote as of


company name or ticker

Recent Quotes

XLRN $29.80 -0.73%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $30.15
Previous Close $30.02
Daily Range $29.51 - $30.86
52-Week Range $23.61 - $48.50
Market Cap $977.8M
P/E Ratio -16.87
Dividend (Yield) $0.00 (0.0%)
Volume 63,391
Average Daily Volume 180,052
Current FY EPS -$1.34

Sector

Industry

CONTROLADORA VUELA SPON ADR REPR 10 CPOS (XLRN) Description

CONTROLADORA VUELA SPON ADR REPR 10 CPOS Website: http://www.acceleronpharma.com/

News & Commentary

Stocks To Watch in Orphan Drugs

Acceleron Pharma, bluebird bio, and Sarepta Therapeutics are three rare disease specialists with upcoming catalysts that could propel their shares higher.

Acceleron Reports Publication in Cancer Research Dalantercept Prevents Metastases in Preclinical Stu

Acceleron Reports Publication in Cancer Research Dalantercept Prevents Metastases in Preclinical Studies of Breast Cancer

Acceleron Announces New Luspatercept Phase 2 Clinical Results at the 20th Congress of the European H

Acceleron Announces New Luspatercept Phase 2 Clinical Results at the 20th Congress of the European Hematology Association

These 3 Ultra-Rare Diseases Are Utterly Terrifying

Despite three decades of intense work leading to over 400 new treatments, we have barely made a dent in the vast unmet medical need for rare diseases. Here is a look at three striking examples underscoring the point.

The Zacks Analyst Blog Highlights: Eleven Biotherapeutics, bluebird, Agios, Acceleron and Achillion

The Zacks Analyst Blog Highlights: Eleven Biotherapeutics, bluebird, Agios, Acceleron and Achillion - Press Releases

Celgene/Accelreon's Luspatercept Granted Fast Track Status - Analyst Blog

Health Care Sector Update for 05/18/2015: CELG, SGYP, EBIO

Trade-Ideas: Acceleron Pharma (XLRN) Is Today's Weak On High Relative Volume Stock

Acceleron Pharma's (XLRN) CEO John Knopf on Q1 2015 Results - Earnings Call Transcript

What is in Store for Aegerion (AEGR) This Earnings Season? - Analyst Blog

See More XLRN News...